Announcements Trials

Browse Landscape

Phase

Phase EARLY_PHASE1 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Carcinoma, Non-Small-Cell Lung 18 Carcinoma, Hepatocellular 11 Stomach Neoplasms 10 Esophageal Squamous Cell Carcinoma 10 Squamous Cell Carcinoma of Head and Neck 9 Lung Neoplasms 8 Colorectal Neoplasms 8 Rectal Neoplasms 5 Advanced Solid Tumor 5 Head and Neck Neoplasms 4 Triple Negative Breast Neoplasms 3 Esophageal Neoplasms 3 Cholangiocarcinoma 3 Urinary Bladder Neoplasms 2 Small Cell Lung Carcinoma 2 Neoplasm, Residual 2 Nasopharyngeal Carcinoma 2 Lymphoma 2 Leukemia, Myeloid, Acute 2 Colonic Neoplasms 2 Biliary Tract Neoplasms 2 Advanced Solid Tumour 2 Uterine Cervical Neoplasms 1 Squamous Cell Carcinoma of External Auditory Canal 1 Solid Tumor, Adult 1 Solid Tumor 1 Small Cell Lung Cancer Extensive Stage 1 Simpson-Golabi-Behmel syndrome 1 Sarcoma 1 Renal Pelvic Carcinoma 1

Interventions

Mitomycin 2 tislelizumab 1 molgramostim 1 cryoprecipitate coagulum 1 Standard of Care 1 Observation 1 Hyperthermic Intraperitoneal Chemotherapy 1 Capecitabine 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Recruiting × Pseudomyxoma Peritonei × tislelizumab × Clear all

NCT07341360 2026-01-14

Pseudovax

Oslo University Hospital

Phase EARLY_PHASE1 Recruiting

Pseudomyxoma Peritonei

Data powered by HemOnc (CC BY 4.0) Colophon ⚡